Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo-Reference-Cited by-同舟云学术

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

Published:2007-11-11 Issue:0 Volume:0 Page:071113214049001-???
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Reddy Nishitha,Hernandez-Ilizaliturri Francisco J.,Deeb George,Roth Mark,Vaughn Mary,Knight Joy,Wallace Paul,Czuczman Myron S.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06841.x/fullpdf

Reference32 articles.

1. Induction of natural killer cell migration by monocyte chemotactic protein−1, −2 and −3

2. The C–C Chemokine MCP-1 Differentially Modulates the Avidity of β1 and β2 Integrins on T Lymphocytes

3. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

4. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

5. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions;Cancers;2024-05-27

2. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial;Nature Medicine;2024-01-04

3. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study;Cancer;2023-11-20

4. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma;Blood Advances;2023-10-30

5. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma;Future Oncology;2023-10